Syndicate content

Phage Display Pioneer & Industry Leader Celebrates Success of Revolutionary Technology Together with 2018 Nobel Laureates in Chemistry

IONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, announced that its Founder and Chief Executive Officer, Dr. John McCafferty (photo), was invited to attend the Nobel Prize Award Ceremony in recognition of his pivotal contribution to the development of antibody phage display technology. The event, held in Stockholm, Sweden, on December 10, celebrated the 2018 Nobel Laureates and the success of phage display technology in modern drug discovery and development, which the Royal Swedish Academy of Sciences recognized in this year’s Nobel Prize in Chemistry (https://www.nobelprize.org/prizes/chemistry/2018/press-release/). Sir Gregory Winter (MRC Laboratory of Molecular Biology, Cambridge, UK) and Dr. George Smith (University of Missouri, Columbia, Missouri, USA) jointly received one half of the Nobel Prize in Chemistry 2018 “for the phage display of peptides and antibodies.” Dr. Frances Arnold (California Institute of Technology, Pasadena, California, USA) was awarded the other half “for the directed evolution of enzymes.” Dr. Smith published his breakthrough paper on display of peptides on filamentous bacteriophage in 1985. Inspired by this, Dr. Winter and Dr. McCafferty then applied the approach to antibody display, with the aim of producing new pharmaceuticals. While working in Dr. Winter’s group, Dr. McCafferty became the first to demonstrate the display of functional antibodies on the surface of phage (McCafferty et al., Nature, 1990) (https://www.nature.com/articles/348552a0). This landmark achievement, cited by the Nobel committee, made it possible to create “libraries” of phage particles containing billions of different human antibody genes from which antibodies to any target could be easily isolated. The technology these scientists developed has proven to be robust and has unleashed a revolution in antibody discovery leading to 11 approved medicines to date with another 41 candidates in clinical trials. In 1989, Dr. Winter, Dr. McCafferty, and Dr. David Chiswell founded Cambridge Antibody Technology (CAT, now MedImmune), which used the technology to develop the human antibody that became Adalimumab (Humira®), currently the world’s highest-selling drug. The technology has since been adopted by many biotech and pharmaceutical companies including AstraZeneca, GlaskoSmithKline, Roche, Genentech, Merck, and Sanofi, for use in antibody discovery and development.

DR. MCCAFFERTY CONGRATULATES LAUREATES

“I offer my congratulations to the winners of the 2018 Nobel Prize for Chemistry and am delighted to have been able to attend the ceremony at Greg Winter’s invitation. I feel proud that the Nobel committee has recognized the importance of our work. The widespread uptake of this technology has had a significant impact on biopharmaceutical pipelines and healthcare, and further development of novel platforms using these techniques will continue to drive antibody discovery forward.”

DR. MCCAFFERTY & IONTAS

Following 12 years at CAT, Dr. McCafferty headed research groups at the Wellcome Trust Sanger Institute and the University of Cambridge, and in 2012, he founded IONTAS, a self-funded, profitable biotech company further developing the next generation of antibody discovery platforms. IONTAS has led the development of a novel technology allowing the construction of very large mammalian display libraries to permit the direct discovery of high-affinity antibodies with optimal biophysical properties. IONTAS has also developed a novel bi-specific fusion molecule (KnotBody) to target ion channels, G-protein-coupled receptors, and proteases.

NEIL BUTT, CHIEF BUSINESS OFFICER, IONTAS, COMMENTS

“The pivotal work achieved by the team at CAT has revolutionized monoclonal antibody drug discovery, and led to major breakthroughs in biopharmaceuticals. John’s contributions to the platform and entrepreneurial success has continued through establishing IONTAS and positioning the company as a leader in the discovery and optimization of fully human antibodies. Our team continues to strive towards developing innovative medicines to benefit all patients through the development of novel technology platforms. These platforms facilitate rapid progression from drug discovery to manufacturing and enhance antibody drug discovery by, for example, generating antibodies against difficult targets such as ion channels.”

JOHN MCCAFFERTY

John McCafferty is from Glasgow, Scotland and received a BSc (Hons) degree from Strathclyde University and a PhD from Glasgow University. In 1990 he was, one of the founders of Cambridge Antibody Technology and initiated work in Greg Winter’s lab leading to the first publication on antibody phage display in 1990. His work also led to the “McCafferty patent” family which underpinned CAT for the next 2 decades (e.g., USA patent no 5,969,108). After leaving CAT, John returned to academia at the Sanger Institute and the University of Cambridge before founding IONTAS in 2012.

IONTAS

IONTAS is a biotechnology company focused on antibody discovery and cutting-edge technology development directed toward protein-based drug discovery. IONTAS was founded by John McCafferty principle inventor of antibody phage display technology and a co-founder of Cambridge Antibody Technology (now Medimmune, Cambridge). IONTAS offers services for antibody discovery using Phage Display Technology; and the supply of bespoke phage display libraries. In addition, IONTAS offers proprietary antibody discovery platforms including Mammalian Display where full-length antibodies are expressed in the context of a mammalian cell thereby allowing selection based on function, stability, expression, and developability; IONTAS has also developed a novel “KnotBody” format that facilitates the targeting of antibodies to ion channels, GPCRs, and proteases.

[IONTAS press release] [2018 Nobel Chemistry press release] [IONTAS]